Align Technology (ALGN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
Q3 revenue was $1,014.8M, up 1.9% YoY and 2.4% at constant currency; Clear Aligner shipments rose 6.6% to 690.6K cases.
Record doctor submitters reached 90.9K, up 3.1%, and utilization rose 3.4%; non-GAAP operating margin reached 24.4%, up 0.5 points YoY.
International growth was offset by soft discretionary spending and capital equipment demand; FY26 revenue guidance was reduced versus the prior outlook.
Financial highlights
Clear Aligner revenue was $839.3M, up 4.2% YoY; revenue per case shipment was $1,215, down 2.3%.
Systems & Services revenue was $175.5M, down 7.6% YoY; like-for-like scanner pricing stabilized amid a shift to lower-priced configurations and flexible acquisition models.
GAAP gross margin was 68.7%; non-GAAP gross margin was 70.4%, flat YoY and ~0.7 points higher at constant currency.
GAAP operating income was $169.2M and non-GAAP operating income was $247.8M; non-GAAP operating income increased $10.0M YoY.
GAAP diluted EPS was $1.90 and non-GAAP diluted EPS was $2.80; FX reduced GAAP EPS by $0.24 YoY.
Outlook and guidance
Q4 revenue guidance is $1.00B–$1.02B; Clear Aligner volume growth is expected in the low single digits YoY, ASP down ~1%, and Systems & Services revenue of $170M–$180M.
Q4 GAAP/non-GAAP gross margin guidance is ~71%/~72%; operating margin guidance is ~20%/~26%.
FY26 revenue guidance is $4.110B–$4.130B; Clear Aligner volume and revenue growth are expected at ~5%–6%, ASP slightly down, and Systems & Services revenue at $715M–$725M.
FY26 GAAP operating margin is expected at ~16.2%; non-GAAP margin at ~23.7%, up ~100 bps YoY. FY26 capex is expected at $125M–$150M.
Preliminary FY27 framework targets revenue growth and at least 100 bps of non-GAAP operating margin improvement, assuming current market conditions and no consumer recovery.
Latest events from Align Technology
- Growth driven by innovation, financing, and international expansion amid stable but challenging markets.ALGN
2026 Global Healthcare Conference - Record Q2 2026 revenue and Clear Aligner growth, with margin expansion and strong cash returns.ALGN
Q2 2026 - Product innovation and digital adoption drive global growth and margin expansion across key regions.ALGN
Leerink Global Healthcare Conference 2026 - Flexible pricing, new financing, and direct fab innovation drive growth amid mixed regional trends.ALGN
Baird Global Healthcare Conference 2025 - International growth, product innovation, and digital adoption drive double-digit gains and margin expansion.ALGN
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Record Q4 and FY2025 results, robust Clear Aligner growth, and strong 2026 outlook.ALGN
Q4 2025 - Q2 2025 saw sequential revenue growth but year-over-year decline and major restructuring plans.ALGN
Q2 2025 - Clear Aligner volume up 6.2% YoY, revenue down 1.8%; margin, volume growth expected in 2025.ALGN
Q1 2025 - Record 2024 revenues and volumes set the stage for 2025 growth despite FX headwinds.ALGN
Q4 2024